Iontas, Teva Enter New Antibody Optimization Agreement

Biotechnology company, Iontas, and Teva Pharmaceuticals have entered into an agreement for the application of technologies and know-how into the optimization of human antibodies to be used as biotherapeutics.

In a July 29, 2019 press statement, it was revealed that under the terms of the agreement Iontas will initially apply its proprietary technologies to provide Teva with a panel of optimized antibodies against a defined target. Additionally, through the agreement, Teva will also have the option to enter further optimization programs in the future, and options for the screening of biophysical properties suitable for developable antibodiesare also included.

“Our experience in both antibody discovery and optimization enables us to generate antibodies that meet the stringent characteristics required by our partners and the selection of IONTAS by Teva is a validation of this know-how and expertise,” said Dr John McCafferty, Founder and Chief Executive Officer of IONTAS, in the press statement. “With our ability to focus on function, affinity, specificity, and developability, we can generate lead antibodies with lower risk of chemistry, manufacturing, and controls issues.”

Source: Iontas